Pęcherzykowe zapalenie jamy ustnej, czynnik etiologiczny - zagrożenia i perspektywy

• Autorzy: Fitzner A.

Warianty tytułu

EN

Vesicular stomatitis and its causative agent: The risks and perspectives

• Języki publikacji: PL

Abstrakty

EN

Vesicular stomatitis (VS) is a viral disease of horses, cattle and swine caused by vesiculoviruses (VSV) of the Rhabdoviridae family. The disease is a zoonosis. VS is endemic in the Western Hemisphere, where its incidence is confined to the warmer regions of North America, as well as Central and South America with tropical climate. The article presents the most important issues concerning the historical background and current status of the disease and its etiological agent. The impact of climatic and ecological conditions on the emergence of new outbreaks and virus strain evolution is discussed, as well as the role of insects in the epidemiology of infections and limited possibilities of specific prevention. The importance of VS virus as a vaccine and oncolytic vector and prospects for its use in the prevention of human infectious diseases and cancer therapy are also highlighted.

Słowa kluczowe

PL

choroby zwierzat; pecherzykowe zapalenie jamy ustnej; etiologia; rabdowirusy; wirus pecherzykowego zapalenia jamy ustnej; wystepowanie; patogeneza; objawy chorobowe; diagnostyka; profilaktyka

• Wydawca: -
• Czasopismo: Medycyna Weterynaryjna
• Rocznik: 2015
• Tom: 71
• Numer: 04
• Opis fizyczny: s.198-205,bibliogr.

Twórcy

autor

Fitzner A.

• Zakład Pryszczycy, Państwowy Instytut Weterynaryjny - Państwowy Instytut Badawczy w Puławach, ul.Wodna 7, 98-220 Zduńska Wola

Bibliografia

• 1. Alonso A., Martins M. A., Gomes M. D., Allende R., Sondhal M. S.: Development and evaluation of an enzyme-linked immunosorbent assay for detection,typing, and subtyping of vesicular stomatitis virus. J. Vet. Diagn. Invest. 1991,3, 3287-292.
• 2. Bachman M. F., Bast C., Hengartner H., Zinkernagel R. M.: Immunogenicity of a viral model after different inactivation procedures. Med. Microbiol. Immunol. 1994, 183, 95-104.
• 3. Bell J. C., Lichty B., Stojdl D.: Getting oncolytic therapies off the ground. Cancer Cell 2003, 4, 7-11.
• 4. Bilsel P. A., Rowe J. E., Fitch W. M., Nichol S. T.: Phosphoprotein and nucleocapsid protein evolution of vesicular stomatitis virus New Jersey. J. Virol.1990, 64, 2498-2504.
• 5. Blondel D., Harmison G. G., Schubert M.: Role of matrix protein in cythopathogenesis of vesicular stomatitis virus. J. Virol. 1990, 64, 1716-1725.
• 6. Brown F., Cartwright B., Crick J., Smale C. J.: Infective virus substructure from vesicular stomatitis virus. J. Virol. 1967, 1, 368-373.
• 7. Brown K. S., Safronetz D., Marzi A., Ebihara H., Feldmann H.: Vesicular stomatitis virus-based vaccine protects hamsters against lethal challenge withAndes virus. J. Virol. 2011, 85, 12781-12791.
• 8. Cantlon J. D., Gordy P. W., Bowen R. A.: Immune responses in mice, cattle and horses to a DNA vaccine for vesicular stomatitis. Vaccine 2000, 18, 2368--2374.
• 9. Cartwright B., Brown F.: Serological relationships between different strains of vesicular stomatitis virus. J. Gen. Virol. 1972, 16, 391-398.
• 10. Cesaire R., Oliere S., Sharif-Askari E., Loignon M., Lezin A., Olindo S., Panelatti G., Kazanji M., Aloyz M., Panasci L., Bell J. C., Hiscott J.: Oncolyticactivity of vesicular stomatitis virus in primary adult T-cell leukemia. Oncogene2006, 25, 349-358.
• 11. Cornish T. E., Stallknecht D. E., Brown C. C., Seal B. S., Howerth E. W.: Pathogenesis of experimental vesicular stomatitis virus (New Jersey serotype) nfection in the Deer Mouse (Peromyscus maniculatus). Vet. Pathol. 2001, 38, 396-406.
• 12. Cotton W. E.: Vesicular Stomatitis. Vet. Med. 1927, 22, 169-175.
• 13. Fernandez M., Porosnicu M., Markovic D., Barber G. N.: Genetically engineered vesicular stomatitis virus in gene therapy: application for treatment ofmalignant disease. J. Virol. 2002, 76, 895-904.
• 14. Ferris N. P., Clavijo A., Yang M., Velazquez-Salinas L., Nordengrahn A., Hutchings G. H., Kristersson T., Merza M.: Development and laboratoryevaluation of two lateral flow devices for the detection of vesicular stomatitisvirus in clinical samples. J. Virol. Methods 2012, 180, 96-100.
• 15. Flanagan B. E., Zamparo J. M., Ball L. A., Rodriguez L. L., Wertz G. W.: Rearrangement of the genes of vesicular stomatitits virus eliminates clinicaldisease in the natural host: new strategy for vaccine development. J. Virol.2001, 75, 6107-6114.
• 16. Geisbert T. W., Feldmann H.: Recombinant vesicular stomatitis virus-based vaccines against Ebola and Marburg virus infections. J.I.D. 2011, 204, 1075- 1081.
• 17. Giedlin M. A., Cook D. N., Dubensky T. W.: Vesicular stomatitis virus: An exciting new therapeutic oncolytic virus candidate for cancer or just anotherchapter from Field’s Virology? Cancer Cell 2003, 4, 241-243.
• 18. Hanson R. P.: The Natural history of vesicular stomatitis. Bact. Rev. 1952, 16, 179-204.
• 19. Hastie E., Grdzelishvili V. Z.: Vesicular stomatitis virus as a flexible platform for oncolytic virotherapy against cancer. J. Gen. Virol. 2012, 93, 2529-2545.
• 20. Hole K., Velazques-Salinas L., Clavijo A.: Improvement and optimization of a multiplex real-time reverse transcription polymerase chain reaction assayfor the detection and typing of Vesicular stomatitis virus. J. Vet. Diagn. Invest.2010, 22, 428-433.
• 21. House J. A., House C., Dubourget P., Lombard M.: Protective immunity in cattle vaccinated with a commercial scale, inactivated, bivalent vesicularstomatitis vaccine. Vaccine 2003, 21, 1932-1937.
• 22. Howerth E. W., Mead D. G., Mueller P. O., Duncan L., Murphy M. D., Stallknecht D. E.: Experimental vesicular stomatitis virus infection in horses:effect of route of inoculation and virus serotype. Vet. Pathol. 2006, 43, 943-955.
• 23. Jonkers A. H., Shope R. E., Aitken T. H., Spence L.: Cocal virus, a new agent in Trinidad related to vesicular stomatitis virus, type Indiana. Am. J. Vet. Res.1964, 25, 236-242.
• 24. Kapadia S. U., Simon I. D., Rose J. K.: SARS vaccine based on a replication-defective recombinant vesicular stomatitis virus is more potent than onebased on a replication–competent vector. Virology 2008, 376, 165-172.
• 25. Kelley J. M., Emerson S. U., Wagner R. R.: The glycoprotein of vesicular stomatitis virus is the antigen that gives rise to and reacts with neutralizingantibody. J. Virol. 1972, 10, 1231-1235.
• 26. Kopecky S. A., Lyles D. S.: The cell-rounding activity of the vesicular stomatitis virus matrix protein is due to the induction of cell death. J. Virol. 2003, 77,5524-5528.
• 27. Letchworth G. J., Rodriguez L. L., Barrera J. C.: Vesicular stomatitis. Vet. J. 1999, 157, 239-260.
• 28. Magnuson R. J., Triantis J., Rodriguez L. L., Perkins A., Meredith C. O., Beaty B., McCluskey B., Salman M.: A single-tube multiplex reverse transcription-polymerasechain reaction for detection and differentiation of vesicularstomatitis Indiana 1 and New Jersey viruses in insects. J. Vet. Diagn. Invest.2003, 15, 561-567.
• 29. Martinez I, Rodriguez L. L., Jimenez C., Pauszek S. J., Wertz G. W.: Vesicular stomatitis virus glycoprotein is a determinant of pathogenesis in swine, a naturalhost. J. Virol. 2003, 77, 8039-8047.
• 30. McCluskey B. J., Beaty B. J., Salman M. D.: Climatic factors and the occurrence of vesicular stomatitis in New Mexico, United States of America. Rev. Sci.Tech. OIE 2003. 22, 849-856.
• 31. Mead D. G., Ramberg F. B., Besselsen D. G., Maré C. J.: Transmission of Vesicular stomatitis virus from infected to noninfected Black Flies co-feedingon nonviremic Deer Mice. Science 2000, 287, 485-487.
• 32. Nichol S. T.: Molecular epizootiology and evolution of vesicular stomatitis virus New Jersey. J. Virol. 1987, 61, 1029-1036.
• 33. Novella S.: Contributions of vesicular stomatitis virus to the understanding of RNA virus evolution. Curr. Op. Microbiol. 2003, 6, 399-405.
• 34. Pol A. N. van den, Davis J. N.: Highly attenuated recombinant vesicular stomatitis virus VSV-12’GFP displays immunogenic and oncolytic activity.J. Virol. 2013, 87, 1019-1034.
• 35. Pringle C. R.: The composition and structure of rhabdoviruses. Rev. Sci. Tech. OIE 1986, 5, 429-442.
• 36. Quiroz E., Moreno N., Peralta P. H., Tesh R. B.: A human case of encephalitis associated with human vesicular stomatitis virus (Indiana serotype) infection.Am. J. Trop. Hyg. 1988, 39, 312-314.
• 37. Rainwater-Lovett K., Pauszek S. J., Kelley W. N., Rodriguez L. L.: Molecular epidemiology of vesicular stomatitis New Jersey virus from the 2004-2005US outbreak indicates a common origin with Mexican strains. J. Gen. Virol.2007, 88, 2042-2051.
• 38. Reichmann M. E., Schniztlein W. M., Bishop D. H. L., Lazzerini R. A., Beatrice S. T., Wagner R. R.: Classification of the New Jersey serotype of vesicular stomatitis virus into two subtypes. J. Virol. 1978, 25, 446-449.
• 39. Reis J. L. jr, Mead D., Rodriguez L. L., Brown C. C.: Transmission and pathogenesis of vesicular stomatitis viruses. Braz. J. Vet. Pathol. 2009, 2, 49-58.
• 40. Roberts A., Buonocore L., Price R., Forman J., Rose J. K.: Attenuated vesicular stomatitis virus as vaccine vectors. J. Virol. 1999, 73, 3723-3732.
• 41. Rodriguez L. L.: Emergence and re-emergence of vesicular stomatitis in the United States. Virus Res. 2002, 85, 211-219.
• 42. Rodriguez L. L., Fitch W. M., Nichol S. T.: Ecological factors rather than temporal factors dominate the evolution of vesicular stomatitis virus. Proc.Natl. Acad. Sci. USA 1996, 93, 13030-13035.
• 43. Rose N. F., Marx P. A., Luckay A., Nixon D. F., Moretto W. J., Donahoe S. M., Montefiori D., Roberts A., Buonocore L., Rose J. K.: An effective AIDS vaccinebased on live attenuated vesicular stomatitis virus recombinants. Cell 2001,106, 539-549.
• 44. Scherer C. F. C., O’Donnell V., Golde W. T., Gregg D., Estes D. M., Rodriguez L. L.: Vesicular stomatitis New Jersey virus (VSVNJ) infects keratinocytes and is restricted to lesion sites and local lymph nodes in the bovine, a natural host. Vet. Res. 2007, 38, 375-390.
• 45. Stallknecht D. E., Nettles V. F., Erickson G. A., Jessup D. A.: Antibodies to esicular stomatitis virus in populations of feral swine in the United States. J. Wild. Dis.1986, 22, 320-325.
• 46. Stojdl D. F., Lichty B. D., tenOever B. R., Paterson J. M. et al.: VSV strains with defects in their ability to shutdown innate immunity are potent systemicanti-cancer agents. Cancer Cell 2003, 4, 263-275.
• 47. Tesh R. B., Chaniotis B. N., Johnson K. M.: Vesicular stomatitis virus (Indiana serotype): Transovarial transmission by phlebotomine sandflies. Science 1972,175, 1477-1479.
• 48. Tesh R. B., Peralta P. H., Johnson K. M.: Ecologic studies of vesicular stomatitis virus. I. Prevalence of infection among animals and humans living in an areaof endemic VSV activity. Am. J. Epidemiol. 1969, 90, 255-261.
• 49. Wagner R. R., Prevec L., Brown F., Summers D. F., Sokol F., Macleod R.: Classification of rhabdovirus proteins: a proposal. J. Virol. 1972, 10, 1228-1230.
• 50. Zhao J., WenY., Li Q., Wang Y.: A promising cancer gene therapy agent based on the matrix protein of vesicular stomatitis virus. FASEB J. 2008, 22, 4272- 4280.